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Nif3-like protein familya b s t r a c t
HcgD, a homolog of the ubiquitous Nif3-like protein family, is found in a gene cluster involved in the
biosynthesis of the iron-guanylylpyridinol (FeGP) cofactor of [Fe]-hydrogenase. The presented crys-
tal structure and biochemical analyses indicated that HcgD has a dinuclear iron-center, which pro-
vides a pronounced binding site for anionic ligands. HcgD contains a stronger and a weaker bound
iron; the latter being removable by chelating reagents preferentially in the oxidized state. Therefore,
we propose HcgD as an iron chaperone in FeGP cofactor biosynthesis, which might also stimulate
investigations on the functionally unknown but physiologically important eukaryotic Nif3-like pro-
tein family members.
Structured summary of protein interactions:
HcgD and HcgD bind by X-ray crystallography (View interaction)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
[Fe]-hydrogenase is one of three classes of hydrogenases [1,2]
and reversibly catalyzes the heterolytic cleavage of molecular
hydrogen; the generated hydride is transferred to methenyl-
tetrahydromethanompterin in a stereo-speciﬁc manner [3,4].
[Fe]-hydrogenase contains a mononuclear iron complex, the iron-
guanylylpyridinol (FeGP) cofactor, which is essential for catalysis
[5]. The iron of the FeGP cofactor is coordinated by two CO, one
cysteine-S, one solvent, and one pyridinol nitrogen and one acyl-
carbon of a pyridinol substituent [6–10]. Because of its unique
structural features, as i.e. the organometallic iron-acyl bond and
the highly substituted pyridinol, the biosynthesis of the FeGP
cofactor is of great interest in chemistry and biology.
Seven highly conserved genes (hcgA–G) are adjacent to the hmd
gene encoding [Fe]-hydrogenase. Their encoded proteins HcgA–G
was postulated to be involved in FeGP-cofactor biosynthesis [4],which has been indirectly supported by recent genetic data from
Methanococcus maripaludis [11]. HcgA was identiﬁed as a radical
SAM enzyme by biochemical evidence, but its physiological func-
tion is not known [12]. We annotated HcgB as a guanylyltransfer-
ase catalyzing the conjugation of GMP and a pyridinol derivative to
the guanylylypyridinol moiety of the FeGP cofactor [13]. Based on
this result and stable-isotope labeling analysis [14], we have pro-
posed that the guanylylpyridinol substrate is synthesized before
formation of the iron center.
HcgD is a member of the Nif3 (NGG1p-interacting factor 3)-like
protein family. The Nif3 protein was ﬁrst identiﬁed in a yeast two-
hybrid screening with the yeast dual regulator protein NGG1p [15].
A Nif3-like protein in mice is expressed throughout the embryonic
development and might be involved in transcriptional regulation
of neural differentiation. Its exact biochemical and physiological
functions are, however, still obscure [16]. Nif3-like proteins might
also be implicated in human diseases [17]. Crystal structures of
Nif3-like proteins have revealed a dinuclear metal-binding site at
the bottom of an interdomain cleft [18–22].
Here, we present the biochemical and crystal structure analyses
of HcgD from Methanocaldococcus jannaschii (protein MJ0927) in
different conditions. Based on the results we proposed a possible
function of the protein in the biosynthesis of the FeGP cofactor.
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2.1. Preparation of HcgD
Escherichia coli BL21(DE3)Star cells that heterologously produce
the His-tagged M. jannaschii HcgD protein (see Supplementary
material for details) were re-suspended in a solution consisting
of 50 mM potassium phosphate pH 7.0, 0.5 M KCl and 20 mM imid-
azole (buffer A) and disrupted by sonication. The supernatant was
collected by centrifugation and loaded onto a Ni2+-charged HiTrap
chelating column (GE Healthcare) equilibrated with buffer A. The
column was washed with buffer A, and proteins were eluted with
a 20–500 mM linear gradient of imidazole in 50 mM potassium
phosphate pH 7.0 and 0.5 M KCl. After desalting the protein frac-
tions with 50 mM potassium phosphate, pH 7.0 and 0.3 M KCl,
the protein solution was incubated with thrombin (10 units/mg
HcgD protein) at 4 C overnight to cleave the His-tag. The His-tag
and thrombin were then removed by Ni2+-charged HiTrap chelat-
ing and HiTrap Benzamidine FF (GE Healthcare) columns equili-
brated with buffer A. Finally, the HcgD fractions were subjected
to a HiPrep Sephacryl S-200 chromatographic step (GE Healthcare)
using 50 mM potassium phosphate pH 7.0 and 0.3 M KCl for equil-
ibration. The pure HcgD isolated was referred to as oxidized HcgD.
To prepare reduced HcgD, oxidized HcgD was incubated with
10 mM sodium dithionite in a Coy chamber under a N2/H2 atmo-
sphere (95%/5%) at room temperature for 3 h. Excess of sodium
dithionite was removed with a desalting PD-10 column (GE
Healthcare). EDTA-treated oxidized HcgD was prepared by incuba-
tion of oxidized HcgD with 0.25 M EDTA at 4 C for more than 12 h
and EDTA-treated, reduced HcgD by incubation of reduced HcgD
with 0.25 M EDTA in a Coy chamber under a N2/H2 atmosphere
(95%/5%) at room temperature for 12 h. After the incubation,
excess EDTA, dithionite (if present), free and EDTA bound Fe ions
were removed by a desalting PD-10 column.
2.2. UV–Vis spectroscopy, Fe quantiﬁcation in a colorimetric assay
and X-ray ﬂorecence scan
UV–Vis spectra of oxidized HcgD, reduced HcgD, and EDTA-
treated HcgD were recorded on a Specord S 600 (Analytik Jena)
with a quartz cell (0.3 cm cell path) at room temperature. Fe in
HcgD was quantiﬁed using Ferene reagent [23] and Zn using
N1-(7-nitro-2,1,3-benzoxadiazol-4-yl)-N1,N2,N2-tris(2-pyridinylm-
ethyl)-1,2-ethanediamine (NBD-TPEA) [24]. X-ray ﬂuorescence
scans on HcgD crystals were performed at the Swiss-Light Source
(Villigen, Switzerland).
2.3. Crystallization of HcgD
Oxidized HcgD (14 mg/mL) and reduced HcgD (18 mg/mL)
stock solutions were prepared in 10 mM MOPS/KOH buffer pH
7.0. For crystallization, 1 lL oxidized HcgD (14 mg/mL) was mixed
with 1 lL of a reservoir solution [35% (v/v) (±)-2-methyl-2,4-pen-
tanediol, 0.2 M NaCl, 0.1 M Tris–HCl pH 7.0]. Reduced HcgD was
crystallized by adding 1 lL reduced HcgD and 1 lL of a reservoir
solution [10% (w/v) PEG8000, 0.2 M NaCl, 5 mM sodium dithionite,
0.1 M Na/K phosphate pH 6.2] under a N2/H2 atmosphere (95%/5%).
Crystals of HcgD with citrate grew from 1 lL HcgD and 1 lL reser-
voir solution [10% (w/v) PEG4000, 10% (v/v) 2-propanol, 0.1 M
sodium citrate pH 5.6]. For crystallization of reduced HcgD with
citrate, 1 lL reduced HcgD was mixed with 1 lL of a reservoir solu-
tion [10% (w/v) PEG4000, 10% (v/v) 2-propanol, 5 mM sodium
dithionite, 0.1 M sodium citrate pH 5.6] under a N2/H2 atmosphere
(95%/5%). EDTA-treated HcgD was crystallized from a solution
composed of 1 lL EDTA-treated HcgD (15 mg/mL) and 1 lL of res-
ervoir solution [2.4 M ammonium sulfate, 0.1 M HEPES-NaOH pH7.0]. Crystallization of EDTA-treated, reduced HcgD succeeded
from 1 lL of EDTA-treated, reduced HcgD (18 mg/mL) and 1 lL
reservoir solution [10% (w/v) PEG8000, 0.2 M NaCl, 5 mM sodium
dithionite, 0.1 M Na/K phosphate pH 6.2] under a N2/H2
atmosphere (95%/5%). HcgD and pyridinol derivatives (5 mM
6-carboxymethyl-2-hydroxypyridine, 5 mM 3,6-dimethyl-2,4-
dihydroxypyridine, or 1.25 mM iron-free FeGP cofactor prepared
by photo-decomposition of extracted FeGP cofactor [10]) were
co-crystallized under the same conditions as described above (Sup-
plementary Fig. S1). All types of crystals were obtained using the
sitting-drop vapor diffusion method at room temperature within
two weeks.
2.4. X-ray data collection and reﬁnement
The crystals were frozen under a cryo-stream of liquid nitrogen
at 100 K. The crystals of reduced HcgD, oxidized and reduced HcgD
with citrate, EDTA-treated HcgD in a reduced state were immersed
into 33% (v/v) ethylene glycol-containing reservoir solutions for
cryo-protection before cryo-freezing. Diffraction data were col-
lected with a PILATUS 6 M detector at beamline X10SA of the
Swiss-Light Source (Villigen, Switzerland) and processed using
XDS [25]. All HcgD structures were solved by molecular replace-
ment with BALBES [26], Molrep [27], or Phaser [28] based on the
crystal structure of a conserved hypothetical protein from Strepto-
coccus pneumoniae TIGR4 (PDB code: 2FYW) as a search model.
Models were built and reﬁned using COOT [29], REFMAC5 [30],
and PHENIX [31]. In the ﬁnal stage of reﬁnement translation/libra-
tion/screw-rotation groups were introduced [32]. Structure valida-
tion was performed using COOT, PHENIX and PROCHECK [33]. The
resulting structures were established at 2.5 Å (oxidized HcgD),
2.5 Å (reduced HcgD), 2.0 Å (HcgD with citrate), 2.0 Å (reduced
HcgD with citrate), 2.8 Å (EDTA-treated HcgD), and 2.3 Å (EDTA-
treated, reduced HcgD). Data collection and reﬁnement statistics
are summarized in Supplementary Table S1. All ﬁgures of proteins
were depicted using PyMOL (Version 1.3r1, Schrödinger, LLC.).
Model coordinates and structure factors were deposited in the
Protein Data Bank under the following accession codes: 3WSD
(oxidized HcgD), 3WSE (reduced HcgD), 3WSF (oxidized HcgD with
citrate), 3WSG (reduced HcgD with citrate), 3WSH (EDTA-treated,
oxidized HcgD), and 3WSI (EDTA-treated, reduced HcgD) (Supple-
mentary Table S1).3. Results and discussion
3.1. Characterization of the metal in HcgD
Oxidized HcgD from M. jannaschii heterologously produced and
isolated from E. coli was slightly yellow, and the UV–Vis spectrum
had two broad shoulder peaks at 320 and 360 nm (Fig. 1). The yel-
low color suggested the presence of iron, as found in the Nif3-
related protein YbgI from E. coli [20], rather than zinc, present in
the Nif3-related proteins YqfO from Bacillus cereus [18] and protein
SA1388 from Staphylococcus aureus [19]. A colorimetric assay using
Ferene reagent revealed absorption of a typical iron-Ferene com-
plex at 593 nmwith 1.7 ± 0.8 irons per monomer (data not shown).
Moreover, X-ray ﬂuorescence spectroscopic measurements on
crystals of HcgD showed an anomalous signal at the iron absorp-
tion edge (not shown). No Zn was detected using NBD-TPEA. The
UV–Vis spectrum of HcgD between 300 and 400 nm changed upon
addition of dithionite; i.e. the peaks at 320 and 360 nm disap-
peared and a shoulder peak emerged at around 330 nm (Fig. 1),
which suggested redox-active metal like iron (Fe3+? Fe2+) bound
to HcgD. These results indicated that HcgD most likely contains
redox-active irons per monomer.
Fig. 1. UV–Vis spectra of oxidized HcgD (solid line), reduced HcgD (dashed line),
and EDTA-treated oxidized HcgD (dotted line).
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Oxidized HcgD and HcgD reduced with dithionite (2.5 mM ﬁnal
concentration after mixing 1 lL of a HcgD protein stock solution
with 1 lL of a reservoir solution containing 5 mM dithionite in
crystallization) were structurally characterized at 2.5 Å resolution
(oxidized HcgD structure is shown in Fig. 2A). Both HcgD struc-
tures are virtually identical (Supplementary Fig. S2). HcgD, like
other members of the Nif3-like protein family (Supplementary
Fig. S3) [18–21], is organized as a hexameric toroid built up of a
trimer of a compact dimer. The dimers are formed by a head-to-tail
arrangement of two HcgD monomers each of them being com-
posed of two similar interlinked a/b domains (Fig. 2A; Supplemen-
tary Fig. 2). The binuclear iron binding site is located at the inner
side of the toroid at the bottom of a wide cleft formed between
the two a/b domains of each HcgD monomer. The potentialFig. 2. (A) Homohexameric structure of oxidized HcgD. The compact dimers are drawn in
irons and the chloride are highlighted as brown and green spheres. Amino acids coordina
the partner subunit to the active site. (C) Iron-binding site of oxidized HcgD with citratsubstrate binding site in front of the binuclear binding site is encir-
cled by Pro72, His103, Thr104, Leu134, Leu176 and Tyr179 as well
as His204 of the partner monomer which partly shields the active
site from bulk solvent. In oxidized and reduced HcgD, the Fe1/Fe2
binding sites are occupied by two irons with an estimated occu-
pancy of ca. 0.48/1.00 and 0.85/1.00, respectively. Independent of
the redox state the two irons are 3.3–3.9 Å apart and ligated by
the same residues that are strictly conserved in HcgD proteins from
different species (Supplementary experimental procedures and
Supplementary Fig. S4). His70-NE2 and Asp107-OD1 and/or -OD2
are coordinated to Fe1 and His71-NE2 and His221-NE2 to Fe2.
The carboxyl group of the side chain of Glu225 is located between
Fe1 and Fe2 to serve as a bridging ligand (Fig. 2B). In addition, fur-
ther non-protein ligands connected to Fe2 were modeled as chlo-
ride and phosphate ions in the oxidized and reduced HcgD
structures, respectively, according to the shape and height of the
electron density (Fig. 2B). The anionic chloride and phosphate ions
further interact with His103, via solvent molecules with
Asn114ND2, Tyr179N, Ser177O and OG as well as with His204-
NE2 of the partner monomer. This type of binding site for an anio-
nic ligand has not been reported in structures, so far, available for
Nif3-like proteins.
Recently, Kuan et al. independently published a preliminary
X-ray crystallographic study on HcgD [22]; the crystallization con-
ditions were different from our study. In January 2014 (just before
the submission of our manuscript), the crystal structures of seleno-
methionine-labeled and native HcgD (PDB codes: 4IWM and
4IWG) were deposited in the RCSB Protein Data Bank, though the
structural article has not been published and metals were not pres-
ent in the structure. Therefore, the structure and properties of the
iron site could not be compared.
3.3. Impact of the chelating reagents citrate and EDTA
According to the postulated reaction scheme of FeGP cofactor
synthesis (Schick et al. [14], Fujishiro et al. [13]), HcgD is
involved in the biosynthesis of the Fe center after forming ared/lightred, gray/green and yellow/blue. (B) Iron-binding site of oxidized HcgD. The
ting the irons, His204 and citrate are drawn as sticks. His204 (blue) protrudes from
e after removal of one iron.
Fig. 3. A proposed function of HcgD in FeGP cofactor biosynthesis. The guanylylpyridinol precursor is converted by uncharacterized enzymes to the intact FeGP cofactor. We
propose that one iron from HcgD could be delivered to a guanylylpridinol precursor. Enzyme reactions for the formation of the acyl- and CO-ligands and their ligation to the
iron (arrows with dashed line and "?" symbols) are not characterized yet.
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several pyridinol compounds to the oxidized and reduced HcgD
by co-crystallization experiments (for chemical structures of the
pyridinol compounds, see Supplementary Fig. S1) but found no
pyridinol compounds in the electron density of the corresponding
crystal structures (data not shown). During structure analysis, we
unexpectedly found that oxidized and reduced HcgD crystallized
in the presence of 50 mM citrate (at a 1:1 protein/reservoir mix-
ture in a crystallization drop) showed very weak electron density
at the iron ion position of the Fe1 site and contained a citrate
bound to the iron ion at the Fe2 site. Because of its very weak elec-
tron density and the limited resolution of the data, we did not
model anything into the Fe1 site of oxidized (Fig. 2C) and reduced
HcgD with citrate (data not shown). As the Fe1 ion appeared to be
removed by citrate due to its chelating properties, the effects of
other chelating reagents were also tested. Both oxidized and
reduced HcgD were treated with 0.25 M EDTA in solution and sub-
sequently free and iron ion bound EDTA were removed by desalt-
ing. Crystal structures of oxidized and reduced HcgD after EDTA
treatment showed very weak electron density at the Fe1 sites as
previously found in the crystal structures of HcgD incubated with
citrate. On the other hand, Fe2 of EDTA-treated HcgD was not
removed, however, ligated with anionic compounds (a sulfate
and a phosphate in the oxidized and reduced HcgD, respectively).
Removal of iron by the chelating agents was conﬁrmed by UV–
Vis spectroscopic and Fe analytical data. In the UV–Vis spectrum
the height of the shoulder peaks between 300 and 400 nm was
lower in the EDTA-treated than in the non-EDTA-treated oxidized
HcgD (Fig. 1). Colorimetric iron analysis resulted in an iron content
of 0.9 ± 0.3 irons per monomer for EDTA-treated, oxidized HcgD
and 1.7 ± 0.8 irons per monomer for isolated HcgD. Interestingly,
the Fe1 site of reduced HcgD appears to be less affected by EDTA.
The EDTA-treated, reduced HcgD revealed an UV–Vis spectrum
not signiﬁcantly changed (data not shown) and an iron content
(1.5 ± 0.4 irons per monomer) only moderately lower compared
to the values of the isolated HcgD. Thus, crystal structure indicated
that the afﬁnity for iron was lower to the Fe1 than to the Fe2 site,
and biochemical assays revealed that the afﬁnity was lower in the
oxidized than in the reduced state.
3.4. Arguments for the function of HcgD as an iron chaperone
Nif3 family proteins are characterized by their dinuclear metal
centers composed of either iron or zinc. Our data clearly indicated
that HcgD contains a dinuclear iron center. A second common fea-
ture of Nif3 proteins might be the binding site for an anionic ligand
at the Fe2 site (or equivalent Zn site), which is occupied with either
chloride, phosphate or citrate in HcgD as well as H2O/OH ligandsin the other Nif3 family structures [19,20]. The ligand-binding
character at the metal clusters in Nif3 family members is
distinct from those of other functionally known enzymes (e.g. iron-
dependent ribonucleotide reductase and methane monooxygen-
ase) [34], which prompts for a different function.
Biosynthesis of many metal-containing cofactors of enzymes
requires metal-trafﬁcking proteins [35], which most likely holds
also true for FeGP cofactor maturation. According to sequence
analysis HcgD is the only Hcg protein that potentially binds an iron
rather than a Fe/S cluster [4], which makes it to an attractive can-
didate as an iron chaperone. The presented biochemical/structural
data for HcgD revealed a stronger (Fe2) and a weaker (Fe1) binding
site; the Fe1 site binds iron weaker under oxidized than under
reduced conditions, which is compatible with a redox-state-depen-
dent release process. A preferential and inducible release of one
iron qualiﬁes HcgD as an Fe chaperone (Fig. 3). The structural data
further suggest that the potential Fe release from HcgD is linked
with the binding of an ligand to Fe2. Residues forming the ligand
binding site are strictly conserved within HcgD family. The physi-
ological ligand for HcgDmight be the guanylylpyridinol, which was
identiﬁed as an intermediate in the FeGP cofactor biosynthesis
[13]. This hypothesis could not be demonstrated by structural
analysis of HcgD co-crystallized with guanylylpyridinol, but might
be still possible as other maturation proteins might modulate HcgD
and/or the guanylylpyridinol to promote iron transfer. The shallow
pocket in front of the diiron center would provide sufﬁcient space
to bind a guanylylpyridinol derivative. Whether Fe1 is accepted by
a guanylylpyridinol compound for further maturation or enzymat-
ically equipped with CO ligands in the HcgD bound state and then
further processed remains open. It has to be considered that the
protein machinery recruited for the complex Fe center maturation
process and the speciﬁc role of HgcD therein is still completely
unclear.
4. Conclusion
The available data about HcgD are in agreement with a function
as an iron chaperone that is involved in supplying an iron in the
FeGP cofactor biosynthesis (Fig. 3). Stimulated by the described
results, further biochemical studies are required to work out the
speciﬁc role of HcgD in iron trafﬁcking and Fe center maturation
orchestrated by various maturation factors. Nif3-related proteins,
widely distributed in the three domains of life, participate in vital
physiological processes; however, the molecular functions of none
of them are elucidated. Because of their high structural similarities,
the metal-releasing and ligand-binding properties of HcgD might
be common features of Nif3-related proteins and pave the path
for further studies. Notably, human NIF3L1 [36] and mouse Nif3l1
T. Fujishiro et al. / FEBS Letters 588 (2014) 2789–2793 2793[16] have been identiﬁed as components for neural differentiation.
The neural differentiation in developing hippocampus is reported
to be affected by perinatal iron deﬁciency [37].
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